FierceBiotech Mar 4, 2026 Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option
FierceBiotech Mar 4, 2026 Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
FierceBiotech Mar 3, 2026 New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
FierceBiotech Mar 3, 2026 Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
FierceBiotech Mar 3, 2026 FDA details rationale for rejecting rare disease gene therapy from Regenxbio
FierceBiotech Mar 3, 2026 MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
FierceBiotech Mar 3, 2026 Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
FierceBiotech Mar 3, 2026 AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal
FierceBiotech Mar 3, 2026 GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
FierceBiotech Mar 3, 2026 HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
FierceBiotech Mar 2, 2026 Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
FierceBiotech Mar 2, 2026 TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
FierceBiotech Mar 2, 2026 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline